Comparison between Novus Loyalty IPO and Q-Line Biotec IPO.
Novus Loyalty IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Q-Line Biotec IPO is a SME Bookbuilding proposed to list at NSE SME.
The total issue size of Novus Loyalty IPO is up to ₹56.79 Cr whereas the issue size of the Q-Line Biotec IPO is up to ₹0.00 Cr. The final issue price of Novus Loyalty IPO is ₹146.00 per share and of Q-Line Biotec IPO is .
| Novus Loyalty IPO | Q-Line Biotec IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹139.00 per share | |
| Issue Price (Upper) | ₹146.00 per share | |
| Issue Price (Final) | ₹146.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1000 shares | |
| Fresh Issue Size | 30,70,000 shares | 70,53,200 shares |
| Fresh Issue Size (Amount) | up to ₹44.82 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 8,20,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹11.97 Cr | up to ₹0.00 Cr |
| Issue Size Total | 38,90,000 shares | 70,53,200 shares |
| Issue Size Total (Amount) | up to ₹56.79 Cr | up to ₹0.00 Cr |
Novus Loyalty IPO opens on Mar 17, 2026, while Q-Line Biotec IPO opens on . The closing date of Novus Loyalty IPO and Q-Line Biotec IPO is Mar 20, 2026, and , respectively.
| Novus Loyalty IPO | Q-Line Biotec IPO | |
|---|---|---|
| Anchor Bid Date | Mar 16, 2026 | |
| Issue Open | Mar 17, 2026 | |
| Issue Close | Mar 20, 2026 | |
| Basis Of Allotment (Tentative) | Mar 23, 2026 | |
| Initiation of Refunds (Tentative) | Mar 24, 2026 | |
| Credit of Share (Tentative) | Mar 24, 2026 | |
| Listing date (Tentative) | Mar 25, 2026 | |
| Anchor Lockin End date 1 | Apr 22, 2026 | |
| Anchor Lockin End date 2 | Jun 21, 2026 |
Novus Loyalty IPO P/E ratio is 49.89, as compared to Q-Line Biotec IPO P/E ratio of .
| Novus Loyalty IPO | Q-Line Biotec IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)Q-Line Biotech Ltd.'s revenue increased by 56% and profit after tax (PAT) dropped by 18% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 95.62 | 96.77 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 70.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 49.89 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹227.03 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 31.74 | 17.66 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 40.40 | 23.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.87 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹2.93 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 27.39 | 23.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Novus Loyalty IPO Retail Individual Investors (RII) are offered 13,64,000 shares while in Q-Line Biotec IPO retail investors are offered 13,64,000 shares. Qualified Institutional Buyers (QIB) are offered 8,10,000 shares in Novus Loyalty IPO and 0 shares in Q-Line Biotec IPO.
| Novus Loyalty IPO | Q-Line Biotec IPO | |
|---|---|---|
| Anchor Investor Reservation | 11,30,000 shares | 0 shares |
| Market Maker Reservation | 2,30,000 shares | 0 shares |
| QIB | 8,10,000 shares | 0 shares |
| NII | 5,86,000 shares | 0 shares |
| RII | 13,64,000 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 38,90,000 shares | 0 shares |
Novus Loyalty IPO subscribed 1.10x in total, whereas Q-Line Biotec IPO subscribed .
| Novus Loyalty IPO | Q-Line Biotec IPO | |
|---|---|---|
| QIB (times) | 1.38x | |
| NII (times) | 1.17x | |
| Big NII (times) | 1.31x | |
| Small NII (times) | 0.88x | |
| RII (times) | 1.82x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.10x |
